of folic/folinic acid are the preferred initial strategies over switching to another DMARD because of the efficacy, long-term safety, and low costs associated with methotrexate. The recommendation is conditional because patient preferences play an important role in the decision whether to continue methotrexate or switch to other DMARDs. Switching to subcutaneous methotrexate is conditionally recommended over the addition of/ switching to alternative DMARD(s) for patients taking oral